Sign In
Buy RETA
$172.36
+0 (+0%)
At Close: Dec 22, 2023
Reata (RETA) Friedreich's Ataxia NDA Gets Priority Review
01:26pm, Friday, 27'th May 2022 Zacks Investment Research
Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. The FDA grants priority review to the NDA for the same. Stock rises.
Reata (RETA) Friedreich's Ataxia NDA Gets Priority Review
10:33am, Friday, 27'th May 2022
Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. The FDA grants priority review to the NDA for the same.
FDA grants priority review to Reata's rare disease drug
02:31pm, Thursday, 26'th May 2022
Shares of Reata Pharmaceuticals Inc. RETA, +3.01% were up 2.4% in trading on Thursday after the company said the Food and Drug Administration granted priority review to the company's experimental trea
Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4
02:45pm, Tuesday, 10'th May 2022 Zacks Investment Research
Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
01:23pm, Tuesday, 10'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Acquires Biohaven For $11B
Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold
Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4
12:03pm, Tuesday, 10'th May 2022
Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue Estimates
11:55am, Tuesday, 10'th May 2022 Zacks Investment Research
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 10.18% and 52.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue Estimates
09:02am, Tuesday, 10'th May 2022
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 10.18% and 52.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
03:37pm, Monday, 09'th May 2022 Zacks Investment Research
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
12:47pm, Monday, 09'th May 2022
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Reata (RETA) Submits NDA for Friedreich's Ataxia Candidate
02:04pm, Monday, 04'th Apr 2022 Zacks Investment Research
Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. It completes the rolling submission of an NDA for the same. Stock rises.
Reata (RETA) Submits NDA for Friedreich's Ataxia Candidate
11:18am, Monday, 04'th Apr 2022
Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. It completes the rolling submission of an NDA for the same.
Reata Pharmaceuticals, Inc. (RETA) Up 3.9% Since Last Earnings Report: Can It Continue?
03:30pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reata Pharmaceuticals, Inc. (RETA) Up 3.9% Since Last Earnings Report: Can It Continue?
12:47pm, Wednesday, 30'th Mar 2022
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock?
Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 14.5%: Will It Continue to Soar?
11:21am, Wednesday, 30'th Mar 2022 Zacks Investment Research
Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further s
